Welcome
Innovative Consulting for Emerging Technologies
Expert guidance in translating science and technology into commercial success
About Bookends Consulting
Who we are
Bookends Consulting, LLC is a strategic advisory firm, founded by David E. Huizenga, Ph.D., J.D. (LinkedIn https://www.linkedin.com/in/david-e-huizenga-ph-d-aa6039a/ ) that advises startups, established companies, universities, non-profit institutions, and government organizations at the intersection of science, technology, law, and business. Drawing on decades of experience in life sciences and engineering innovation, product development, and commercialization, the firm excels at providing tailored, cross disciplinary guidance to its clients. With a proven track record of monetizing innovation through company formation, fundraising, licensing, and technology transfer, the firm offers deep expertise in building scalable and investable ventures. Areas of sector expertise include the high impact areas of pharmaceuticals, biotechnology, medical devices, digital engineering and science, digital health and health data, genomics and precision medicine, health services, telemedicine, home health, pain management, antimicrobial resistance, antivirals, and the drug discovery pipeline.
Dr. Huizenga’s leadership in high-impact, multidisciplinary teams—across government-funded projects and commercial enterprises—equips clients to navigate regulatory landscapes, protect and commercialize IP, secure funding, and advance cutting-edge technology from lab to market.
With decades of leadership experience in early-stage company formation, venture financing, IP strategy, and commercialization, Dr. Huizenga brings unique insights to problems as they present.
Our Mission
To empower visionary organizations by transforming breakthrough ideas into high-impact innovations through strategic counsel that integrates science, law, and business.
Our Vision
To be the leading advisory firm enabling the next generation of health, science, and engineering innovation by bridging the gap between discovery and commercial success.